Welcome!

Thank you for your interest in NeuroAiD*.

This section is dedicated to medical professional. Here you can review NeuroAiD’s clinical data, read about its pharmacology, go through publications, and assess the relevance of NeuroAiD in your practice and for your stroke and traumatic brain injured patients.

For more information, do not hesitate to contact us by email at medical@moleac.com

 

*Note: NeuroAiD™ (MLC601) is the original formula composed by 14 ingredients. NeuroAiD™ II and NurAiD™ II (MLC901) are simplified formulas of NeuroAiD™ (MLC601) composed with the 9 herbal ingredients of the original formula. MLC901 and MLC601 have been shown to be pharmacologically equivalent. In the interest of simplification, the following information will use NeuroAiD as a global name to designate the products except in case of specific mentions.

NeuroAiD is a natural product indicated for post-stroke recovery and post-traumatic brain injury (TBI) recovery.

 

Following national regulations in each country, NeuroAiD is registered under various schemes, which includes dietary supplement, traditional medicine and herbal medicine. To date, NeuroAiD is available in over 32 countries worldwide and is continuously expanding its development.

With the support and involvement of international key opinion leaders in Neurology and experienced researchers, NeuroAiD has gathered over 45 publications from pre-clinical studies to randomized clinical trials, and aims at addressing a worldwide medical need.

  1. Young S, et al. Safety profile of MLC601 (NeuroAiD) in acute ischemic stroke patients: A Singaporean substudy of the Chinese medicine NeuroAiD efficacy on stroke recovery study. Cerebrovascular Diseases 2010;30:1-6.
    2. Gan R, et al. Danqi Piantan Jiaonang does not modify haemostasis, haematology, and biochemistry in normal subjects and stroke patients. Cerebrovascular Diseases 2008;25:450-456

Prescription general Information

The recommended dosage is 2 capsules at a time, 3 times daily, for a minimum of 3 months.

 

Route of administration

Oral route with a glass of water. For people with swallowing difficulties, it is possible to open the capsules and to dilute the content in water. It is also possible to administer the diluted content via a gastric tube.

 

Interactions

To date, no drug interactions with NeuroAiD have been reported. For more information on NeuroAiD’s safety profile, click HERE.

 

Side effects

Published clinical trials have confirmed that NeuroAiD has no blood thinning effect or effect on liver or renal functions. Similarly, NeuroAiD has neither any effect on blood pressure, and doesn’t induce any change in cardiac, hematological, hemostatic and biochemical parameters.1,2

Clinical trials on NeuroAiD reported only rare cases of nausea, minor headaches, increased thirst, dry mouth and vomiting for patients taking NeuroAiD. In these cases, it is advised to halve the dose of NeuroAiD for a few days and progressively increase it.

 

Contraindications

The use of NeuroAiD in pregnant women, lactating women and children is not documented, and cannot be recommended. To date, no other contraindications are known.

 

Clinical Data

Amplification of brain self-repair processes translating into persistent functional recovery.

A 3-month course with NeuroAiD:

  • Increases by 50% the odds of achieving functional independence at 6 months.1

  • Enhances persistent functional recovery and independence on top of rehabilitation for up to 2 years.1,2,3

  • Improves motor recovery with benefits observed as early as 1 month of treatment and at each time point up to 3 months.4

The CHIMES-E Study, functional recovery over 2 years.1

  • Pre-planned study on 880 subjects* with Acute Ischaemic Stroke followed up for 2 years.

  • Randomised to 3 months of either NeuroAiD or placebo.

+50% in odds of achieving functional independence at 6 months.

Persistent recovery with benefits observed over 2 years

In subjects with 2 to 4 prognostic factors of poorer outcome** and receiving NeuroAiD2 :

  • More subjects achieved functional independence over time versus placebo.

  • Significant improvements observed as early as 3 months.

  • Less subjects deteriorating over time versus placebo, illustrating the persistence of the recovery

*CHIMES-E published in Cerebrovascular Diseases journal is the pre-planned extended follow-up to 24 months of the CHIMES study5, a 3-month study conducted on 1099 subjects. The CHIMES study was published in Stroke journal in 2013. **Prognostic factors are defined as older age, female sex, baseline NIHSS score ≥ 10 and time to first dose 48h.  

Combining NeuroAiD and Rehabilitation doubles the odds of achieving functional independence versus Rehabilitation alone.3  

  • Analysis of 380 subjects having received rehabilitation during 3 months of NeuroAiD (n=200) or placebo (n=180).

+50% in odds of achieving functional independence at 6 months.

Persistent recovery with benefits observed over 2 years

  • Statistically significant odds ratio at all time points from 3 months to 2 years from stroke onset.

  • Persistent recovery with benefits sustained for up to 2 years, as supported by low Numbers Needed to Treat (NNT) range from 5 to 7 over the 24-month follow-up period.


NeuroAiD improves motor recovery.4

  • Randomised double-blind study placebo-controlled study in post-acute stroke subjects with upper and lower limbs deficits, included up to one month following an ischaemic stroke (n=150).

Significantly better motor recovery observed since month 1 and sustained up to month 3.

By stimulating brain neurorepair processes, NeuroAiD enhances recovery after a TBI

  • Improves 2 of the most commonly impacted cognitive domain post-TBI6

  • Enhances functional outcome to reach independency in moderate and severe TBI7


The BRAINS study6

  • Randomized, placebo-controlled pilot trial on 79 mild to moderate TBI subjects.

  • Recruited from 1 month to 12 months from TBI.

  • Receiving 6 months of NeuroAiD or matching placebo and followed-up until 9 months.

NeuroAiD significantly improves Executive Functioning and Complex Attention at 6 months.

  • Continuous improvement of Executive Functioning, significant at 6 months.

  • Executive Functioning deficit is directly impacting activities of daily living and affecting cognitive rehabilitation.

  • Continuous improvement of Complex Attention, significant at 6 months.

  • Complex Attention is one of the most impacted cognitive domains following a TBI.


Recovering functional outcomes post-TBI7

  • Randomised, double-blind, placebo-controlled trial in 81 subjects after a moderate to severe TBI.

  • Treatment initiated within 24 hours from TBI onset from a 6-month course.

  • Dosing schedule: NeuroAiD (MLC901) or placebo at a regimen of 2 capsules, 3 times per day for 6 months.

  • Assessment: GOS and modified Rankin Scale (mRS) at month 3 and month 6.

NeuroAiD optimises recovery of moderate and severe TBI subjects over time

  • Higher rate of subjects with favourable outcome in NeuroAiD group compared to placebo group at month 3.

  • Over 86% of the subjects reached favourable outcome in NeuroAiD group after a 6-month course (including 43.2% with GOS 5).

  • Significant differences in favour of NeuroAiD at both time points.

  • More subjects reached functional independence (mRS 0-1) in NeuroAiD group vs placebo at month 3 and month 6.

  • The proportion of subjects with no symptoms (mRS 0) is superior in NeuroAiD group compared to the placebo group at both time points.

  • Significant differences in favour of NeuroAiD at both time points.


Visit the Publications tab

for more information on NeuroAiD’s clinical data

References:

  1. Venketasubramanian N, et al. CHInese Medicine NeuroAiD Efficacy on Stroke recovery – Extension Study (CHIMES-E): A multicenter study of long-term efficacy. Cerebrovascular Dis. 2015; 39:309-318.
  2. Venketasubramanian N, et al. Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study. Cerebrovascular Dis. 2017; 43:36–42.
  3. Suwanwela NC, et al. Effect of Combined Treatment with MLC601 (NeuroAiDTM) and Rehabilitation on Post-Stroke Recovery: The CHIMES and CHIMES-E Studies. Cerebrovasc Dis. 2018 doi: 10.1159/000492625.
  4. Harandi AA, et al. Safety and efficacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial. Stroke Research and Treatment. 2011; doi:10.4061/2011/721613.
  5. Chen C, et al. Chinese medicine Neuroaid efficacy on stroke recovery – A double-blind, placebo-controlled, randomized study. Stroke. 2013; 44:2093-2100.
  6. Theadom A, et al. MLC901 (NeuroAid II™) for cognition after traumatic brain injury: A pilot randomised clinical trial. Eur J Neurol. 2018;25(8):1055-e82.
  7. Pakdaman H, et al. MLC901 for moderate to severe traumatic brain injury: pilot, randomised, double-masked, placebo-controlled trial. Open Acc J Comp & Alt Med. 2020; 2(5).OAJCAM.MS.ID.000148. DOI: 10.32474/OAJCAM.2020.02.000148.

NeuroAiD has a favourable safety profile and is well-tolerated

The safety profile of NeuroAiD is well established in ischemic stroke patients and TBI patients. Most of the studies made on NeuroAiD were comparative to placebo. There is no better comparator to assess the safety profile of a product.

  • No interaction with the standard treatments used in post-stroke management or post-TBI management.1,3
  • No change in cardiac, haematological, haemostatic, biochemical parameters.3,4
  • No serious side effects associated with NeuroAiD during treatment1. Rare, transient and mild side effects (e.g., gastrointestinal symptoms) were reported1. These are usually resolved by halving the dose for a few days.
  • No increase in delayed adverse events after treatment completion and a follow-up of 2 years.2,5

NeuroAiD is safe as an add-on treatment for neurological recovery.

To date, no drug interactions with NeuroAiD have been reported.

NeuroAiD should be taken in addition to preventive treatments of cardiovascular risk factors commonly prescribed after a stroke; these typically include antiplatelet, antihypertensive, and cholesterol-lowering drugs, among others such as anti-diabetics.

Systematic clinical trials have shown that NeuroAiD does not have any interaction with aspirin. Patients taking NeuroAiD with anticoagulants have reported no impact on their INR (International Normalized Ratio). Nevertheless, it is recommended to keep monitoring INR when NeuroAiD is initiated as it is routinely done for patients taking anticoagulants.

 

Quality Control

NeuroAiD is manufactured in Singapore under the international standards of Good Manufacturing Practice (GMP). The GMP standards are applied to procedures in manufacturing dietary supplements, including approval of raw materials, production and process controls, laboratory testing, and product packaging, labelling, and distribution. These processes are regularly audited by independent health authorities.

Every batch of NeuroAiD is analysed thoroughly by third-party independent laboratories to confirm compliance with international standards, ensuring utmost ensuring utmost security of NeuroAiD use.

  1. Chen C, et al. Chinese medicine NeuroAiD efficacy on stroke recovery: A double-blind, placebo-controlled, randomized study. Stroke 2013a;44:2093-2100
    2. Venketasubramanian N, et al. CHInese medicine NeuroAiD efficacy on stroke recovery – Extension study (CHIMES-E): A multicenter study of long-term efficacy. Cerebrovascular Diseases 2015;39:309-318.
    3. Young S, et al. Safety profile of MLC601 (NeuroAiD) in acute ischemic stroke patients: A Singaporean substudy of the Chinese medicine NeuroAiD efficacy on stroke recovery study. Cerebrovascular Diseases 2010;30:1-6.
    4. Gan R, et al. Danqi Piantan Jiaonang does not modify haemostasis, haematology, and biochemistry in normal subjects and stroke patients. Cerebrovascular Diseases 2008;25:450-456.
    5. Shahripour RB, et al. A Randomized Trial to Assess the Long-Term Safety of NeuroAiD among Caucasian Patients with Acute Ischemic Stroke. Chin J Integr Med 2014;20(11):812-817.

NeuroAiD: Pharmacological Data

NeuroAiD has a multi-target mode of action to boost the main components of endogenous neurorepair and exerts a priming effect on neurorepair by simultaneously activating pharmacological pathways

NEURONAL NETWORK PLASTICITY1,2

  • Increases survival, neuronal network strengthening and plasticity, and neurogenesis by upregulating Brain-Derived Neurotrophic Factor (BDNF).
  • Increases neurite outgrowth and synaptogenesis.
  • Promotes a denser axonal and dendritic network.

NEUROGENESIS1,2

  • Increases the number of newly generated neurons and glial cells.
  • Optimizes their migration and differentiation into fully functional cells.

ANGIOGENESIS3

  • Reduces the leakage of the Brain Blood Barrier and optimizes its repair. Modulates the expression and activity of the mediators involved in neuroinflammation.
  • Amplifies the development of micro vessels in the damaged area

NEURO-INFLAMMATION MODULATION4

  • Reduces the leakage of the Brain Blood Barrier and optimizes its repair.
  • Modulates the expression and activity of the mediators involved in neuroinflammation.

NeuroAiD increases Brain Derived Neurotrophic Factor (BDNF) production1

BDNF is a growth factor which regulates neuronal survival and protects neurons from glutamate-induced damages. BDNF also encourages proliferation and differentiation of new neurons.

In vivo effect of NeuroAiD pre-treatment on BDNF protein levels in cortex sections. (A) Representative epifluorescence microscopy photographs of BDNF immunoexpression in cortical neurons in brain sections. (B) Quantification of BDNF signal intensity in immunostained neurons.

NeuroAiD promotes denser neuronal networks1

Epifluorescence microscopy confirmed the development of an important axonal and dendritic network on cell cultures with NeuroAiD.

On day 14, in neuronal cell cultures treated with NeuroAiD, epifluorescence showed a remarkable increase of DCX, GAP43 and Synaptotagmin expressions, providing evidence that NeuroAiD triggers:

  • Neurogenesis

  • Neurite outgrowth

  • Synaptogenesis

NeuroAiD promotes both the development of new synaptic connections and the modification of existing ones, including an increase in the number and length of dendrites and synapses. A 60% increase in the length of the neurite was shown at Day 14 for NeuroAiD group.

Effects of MLC601/MLC901 treatment on in vitro Synaptotagmin 1 expression in cultured cortical neurons. Synaptotagmin 1 expression was analyzed after MLC601/MLC901 treatment (1 mg/ml) at Day 7 and 14 of treatment.

 

NeuroAiD promotes neuroplasticity and neurogenesis to support stroke recovery1

 

  • NeuroAiD increases proliferation of neuronal progenitor cells by a significant 3-fold effect (p<0.01) in human stem cells.

  • NeuroAiD increases the number of mature neurons by a significant 2.1-fold effect (p<0.01) in animal studies.

  • Cell cultures treated with NeuroAiD have denser networks of connections with stronger neurons.

Neurogenic effects of MLC901 on human ESC-derived progenitors. (D) Radiant rosette-like aggregates of nestin-positive neural progenitors spontaneously form in low-density cultures. (E) Quantification of the number of rosettes 2 days after the addition of MLC901 (*P < 0.05, **P < 0.01 versus control).

 

The combination of its selected 9 herbal ingredients has a priming effect on neurorepair

to achieve global functional recovery.

 

  • As a priming strategy, NeuroAiD enhances natural neurorepair processes of neurogenesis1,2, neuronal network plasticity1,2, angiogenesis3 and anti-inflammation4.

  • These effects add to the consolidation effects provided by rehabilitation to strengthen the newly formed connections and achieve global functional recovery.

Visit the Publications tab

for more information on NeuroAiD’s properties and mode of action

References

  1. Heurteaux C, et al. Neuroprotective and neuroproliferative activities of NeuroAiD (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology. 2010;58:987-1001.
  2. Quintard H, et al. MLC901, a Traditional Chinese Medicine induces neuroprotective and neuroregenerative benefits after Traumatic Brain Injury in rats. Neuroscience. 2014;277:72-86.
  3. Gandin C, et al. MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice. Cerebrovasc Dis. 2016;42:139–154.
  4. Widmann C, et al. The Traditional Chinese Medicine MLC901 inhibits inflammation processes after focal cerebral ischemia. Scientific Reports. 2018;8:18062.

 

I. Ischemic Stroke

Clinical data – Efficacy

Key Data

The CHIMES-E study, a planned extension study of the CHIMES study, aimed to evaluate the effects of an initial 3-month treatment with NeuroAiD on long-term outcomes of up to 2 years. This study has showed that NeuroAiD increases significantly the odds of achieving functional independence at 6 months and persisted up to 18 months after a stroke, as measured by mRS dichotomy 0-1. It also provided further long-term safety data on NeuroAiD, even when combined with other stroke treatments. The authors concluded that an initial 3-month treatment with NeuroAiD increased the odds of functional independence after a stroke, “providing level 1 evidence of benefit in ischaemic stroke”*. *Venketasubramanian N, et al. As presented at ESOC Glasgow and ESC Vienna 2015
Venketasubramanian N, et al. Cerebrovascular Diseases 2015. DOI: 10.1159/000382082
Click here to open the publication
In this study, the CHIMES investigators assess the effects of combining NeuroAiD and rehabilitation. While patients show substantial neurological improvement due to endogenous mechanisms after stroke, they are often not sufficient to achieve complete recovery in many patients. Hence neurorehabilitation remains one of the cornerstones for poststroke management. NeuroAiD has been shown to enhance the inherent neurorestorative and neurorecovery mechanisms after stroke. This paper reports a more significant effect size in the NeuroAiD and persistent rehabilitation vs placebo and persistent rehabilitation group, in comparison with the NeuroAiD vs Placebo effect size in the overall population. NeuroAiD and rehabilitation together can enable more than double the chance to reach independence at 6 months and 1 year. This study supports a probable beneficial effect of combining NeuroAiD and rehabilitation brain repair processes.
Suwanwela et al. Cerebrovasc Dis 2018. DOI: 10.1159/000492625
Click here to open the publication
This is a sub-analysis of the CHIMES-E study. The researchers aimed to evaluate the recovery pattern and the influence of prognostic factors on treatment effect of NeuroAiD over 2 years. The sustained benefits of NeuroAiD over 2 years were due to more subjects with poorer prognosis improving to functional independence at month 6 and beyond compared to placebo. Selection of subjects with poorer prognosis, particularly those with more severe NIHSS score and longer OTT delay, as well as a long follow-up period, may improve the power of future trials investigating the treatment effect of neuroprotective or neurorestorative therapies.
Venketasubramanian N, et al. Cerebrovascular Diseases 2016. DOI: 10.1159/000452285
Click here to open the publication
This publication is a post-hoc analysis performed on data from subjects included in the CHInese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study. The CHIMES study is an academic international double-blind placebo-controlled clinical trial which treated and monitored 1100 patients from several countries who had suffered an ischemic stroke of intermediate severity within 72 hours, for 3 months. Early vascular events were defined as a composite of recurrent stroke, acute coronary syndrome, and vascular death occurring within 3 months of stroke onset. The research concluded that the risk of early vascular events during the 3-month follow-up was significantly reduced by half in the MLC601 group as compared to the placebo group without an increase in nonvascular deaths. Kaplan–Meier survival analysis demonstrated the difference in risk as early as the first 14 days after stroke.
Chen C, et al. Stroke 2013. DOI: 10.1161/STROKEAHA.113.003226
Click here to open the publication
The CHIMES study is an academic international double-blind placebo-controlled clinical trial which treated and monitored 1100 patients from several countries who had suffered an ischemic stroke of intermediate severity within 72 hours, for 3 months. The research concluded that NeuroAiD is statistically no better than placebo in improving outcomes at 3 months when used among patients with acute ischemic stroke of intermediate severity. However the results of the study confirmed the overall benefit of NeuroAiD in stroke recovery and showed that treatment effect for achieving functional independence was greater among non-acute strokes, consistent with previous studies. In addition the study showed that NeuroAiD had an excellent safety profile.
Chen C, et al. Stroke 2013. DOI: 10.1161/STROKEAHA.113.002055
Click here to open the publication
A pre-specified country analysis of subjects from the Philippines in the CHInese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) Study, published in 2014, showed significantly improved functional and neurological outcomes on NeuroAiD at month 3. With this new analysis, the researchers showed that the beneficial effect of NeuroAiD seen at month 3 in the Filipino cohort is durable up to two years after stroke.
Navarro JC, et al. International Journal of Stroke 2016. DOI: 10.1177/1747493016676615
Click here to open the publication
This study of 150 Iranian patients with a recent ischemic stroke (within 1 month) shows that MLC601 improves motor recovery as early as 4 weeks and persisted up to 12 weeks after stroke. Moreover, good tolerability to treatment was shown and adverse events were mild and transient. No severe adverse event leading to drug discontinuation was reported.
Harandi AA, et al. Stroke Res Treat 2011. DOI: 10.4061/2011/721613
Click here to open the publication
This paper reviews the important findings on NeuroAiD™, from pharmacological properties to efficacy and safety data in Stroke recovery. It reminds that NeuroAiD has demonstrated neurorestorative and neuroprotective properties and this justifies its use from the postacute to chronic phase of stroke. Clinical benefits have shown that it helps achieve functional independence with 63% increase in the odds of achieving independence in patients with established deficits and enhances recovery of motor functions. In addition, NeuroAiD offers a better protection by reducing early cardiovascular events and deaths by 50% after a stroke.
Dib M, et al. European Journal of Medicinal Plants 2014. DOI: 10.9734/EJMP/2015/13192
  Click here to open the publication

Additional Data

This randomized double-blind placebo-controlled study recruited 80 patients within 1 week of stroke, of which 40 received 4 capsules of NeuroAiD 3 times a day and 40 others received placebo for 3 months. The subjects were recruited at Ahvaz Golestan Hospital in Iran from April 2009 to March 2010. This study shows that MLC601 improves cerebral blood flow velocity in post-cerebral infarction subjects better than in the control group. This is associated with more improvement in functional outcome (Barthel Index of activities of daily living) as compared to placebo at 3 months.
Shahripour RB, et al. Eur Intern Med 2011. DOI: 10.1016/j.ejim.2011.01.002
Click here to open the publication
In the clinic, the natural recovery rate of homonymous hemianopsia caused by occipital lobe infarction is low. This prospective study compared the effects of NeuroAiD (MLC601) versus piracetam in improving visual field defects in 40 patients matched for age and sex within 1 week of PCA infarction with pure homonymous hemianopsia. After 3 months of treatment, the findings suggest that MLC601 is superior to piracetam for reducing quantitative visual field defects in homonymous hemianopsia patients.
Ghandehari K, et al. Neural Regen Res 2011. DOI: 10.3969/j.issn.1673-5374.2011.06.003
Click here to open the publication
The authors’ purpose was to verify if patient selection based on two prognostic actors (ie, stroke severity and time to treatment) improves detection of a treatment effect with MLC601. Analyses were performed using data from the CHIMES Study (international, randomized, placebo-controlled, double-blind trials comparing MLC601 to placebo in patients with ischemic stroke of intermediate severity in the preceding 72 hours). MLC601 treatment effects were much higher in the subgroups with prognostic factors than for the entire group and the highest treatment effect was seen among patients with both prognostic factors. It can be concluded that patient selection appears to be an important factor for consideration when designing clinical trials in stroke to better reveal the treatment effect and provides new insights for futures trials.
Venketasubramanian N, et al. Journal of Evidence-Based Medicine 2015. DOI: 10.1111/jebm.12170
Click here to open the publication
This publication updates the 2-study meta-analysis published in Stroke journal in 2009 with all clinical data available since on NeuroAiD and provides an overall assessment of the effects of NeuroAiD in improving functional and motor outcomes by the end of treatment. In a systematic review this paper shows that previous studies on NeuroAiD in ischemic stroke in general were of low risk of bias. The meta-analysis showed a statistically significant beneficial effect in favor of NeuroAiD on functional outcome when assessed at the end of study treatment. Although the results did not reach statistical significance, the overall effects on motor recovery were also in favor of NeuroAiD.
Siddiqui FJ, et al. Cerebrovasc Dis 2013. DOI: 10.1159/000346231
Click here to open the publication
This publication is a pre-planned analysis performed on subjects from the Philippines included in the CHIMES Study. The authors found a statistically significant treatment effect in favour of NeuroAiD™ in the primary outcome of mRS and other secondary outcomes (NIHSS and Barthel Index). This result was likely attributable to the inclusion of patients with more severe stroke and longer delay from stroke onset to treatment initiation in the Philippines cohort. Thus the favourable treatment of NeuroAiD was best demonstrated among postacute stroke patients with moderate severity.
Navarro J, et al. Int J Stroke 2014. DOI: 10.1111/ijs.12324
Click here to open the publication
The National Institutes of Health Stroke Scale (NIHSS) is composed of 15 items. The purpose of this study was to compare the measurement properties of the original NIHSS with shortened versions (including only 11, 8 and 5 items). The analyses were performed using the data from the CHIMES study at Day 10 and 3 months. The original 15-item NIHSS, which can be performed easily over a few minutes, retained information that made it more discriminative and responsive to change than the shortened versions. The authors recommend to use the full version NIHSS, to evaluate patients’stroke severity in clinical trials.
Fabiaña NL, et al. Journal of Clinical Neuroscience 2016. DOI: 10.1016/j.jocn.2016.04.013
Click here to open the publication
This publication is a post-hoc analysis performed on CHIMES study patients. The authors have identified predictors of poorer mRS at 3 months (Age > 60; Female sex; Baseline NIHSS 10-14; Stroke onset to initiation of MLC601 > 48h) and have shown that NeuroAiD™ treatment effect is statistically significant for patients with 2 or more predictors of poorer outcome. Hence this paper illustrates NeuroAiD™ efficacy at 3 months, which is best demonstrated among patients with poorer prognosis.
Chankrachang S, et al. J. of Stroke and Cerebro Diseases 2015. DOI: 10.1016/j.jstrokecerebrovasdis.2014.11.017
Click here to open the publication
This paper aimed to assess the efficacy of MLC601 on functional recovery in patients given MLC601 after an ischemic stroke. This was a retrospective cohort study comparing 30 post-stroke patients given open-label MLC601 for three months and 30 matching patients who did not receive MLC601 from the Stroke Data Bank. There were positive results from this study: NeuroAiD has been shown to improve functional recovery at 3 months post-ischemic stroke.
Navarro JC, et al. Rehabil Res Pract 2012. DOI: 10.1155/2012/506387
Click here to open the publication
The National Institutes of Health Stroke Scale (NIHSS) is composed of 15 items. The purpose of this study was to compare the measurement properties of the original NIHSS with shortened versions (including only 11, 8 and 5 items). The analyses were performed using the data from the CHIMES study at Day 10 and 3 months. The original 15-item NIHSS, which can be performed easily over a few minutes, retained information that made it more discriminative and responsive to change than the shortened versions. The authors recommend to use the full version NIHSS, to evaluate patients’ stroke severity in clinical trials.
Lee CF, et al. Stroke 2016. DOI: 10.1161/STROKEAHA.115.011657
Click here to open the publication
The paper reports the pooled analysis of two randomized controlled clinical trials (initial stroke trials in China) that included 605 patients recruited between 2 weeks and 6 months after their stroke. The results show that patients on NeuroAiD have 2.4 times more chances of achieving independence after 1 month of treatment, and have a 25% better recovery in motor impairments. No serious adverse event was reported.
Chen C, et al. Stroke 2009. DOI: 10.1161/STROKEAHA.108.531616
Click here to open the publication
The aim of this phase II double-blind placebo controlled study was to investigate the efficacy of NeuroAiD on motor recovery in ischemic stroke patients using rehabilitation endpoints in order to provide predictive information for further larger trials. In this clinical trial, 20 patients within 1 month post-stroke received 4 capsules of NeuroAiD 3 times a day for 4 weeks and 20 other patients received placebo. While no statistical significance was detected for all primary and secondary endpoints due to the small sample size, subgroup analysis show trends for better outcome with NeuroAiD for more severe strokes, posterior strokes, and strokes with potential for recovery at 8 weeks.
Kong KH, et al. Cerebrovasc Dis 2009. DOI: 10.1159/000247001
Click here to open the publication
This case series report deals with 10 patients who received NeuroAiD after an ischemic stroke as confirmed on brain imaging (MRI). Conducted in an outpatient private clinic in Mount Alvernia Hospital in Singapore, the report suggests that NeuroAiD can be considered as an add-on treatment to other medications including anti-platelet, warfarin, lipid-lowering, anti-hypertensive, anti-diabetic, and antidepressant medications.
Siow C, Eur Neurol 2008. DOI: 10.1159/000155220
Click here to open the publication
This paper is a review of the related Medline literature (presenting the neuroprotective and neurorestorative properties of the product demonstrated in several pre-clinical studies and also its benefits in post-stroke patients supported by clinical trials including CHIMES and CHIMES-E studies) and a primary stroke center experience to support the availability of NurAiD II for post-stroke patients.
De Le Cruz Cosme C. International Journal of Clinical Neurosciences and Mental Health 2017. ABSTRACT. http://moleac.com/pubs/nuraid-ii_in_stroke_recovery_scientific_reasoning_and_real-world_evidence_-__de_la_cruz_et_al_-_2017.pdf
Click here to open the publication

Clinical data – Safety

Key Data

This exploratory post-hoc analysis from the CHIMES study compared MLC601 vs. placebo in terms of serious adverse events (SAEs) and their clinical impact. Among 1087 subjects from CHIMES, there were 135 subjects with SAEs: 60 on MLC601 and 75 on placebo. Subjects on MLC601 had lower rates of harmful clinical impacts. The rate of subjects with prolonged hospitalisation was threefold lower with MLC601. These findings could translate to reduced healthcare burden and reduced medical costs from stroke.
Venketasubramanian N, Moorakonda RB, Lu Q et al. Cerebrovasc Dis 2020. DOI: 10.1159/000506070
Click here to open the publication
This study on 150 patients with acute ischemic stroke within 1 week of onset demonstrates the long-term (up to 6 months) safety of NeuroAiD in a Caucasian population. While mild nausea was more commonly reported in the NeuroAiD group, none of the reported adverse events were serious or required discontinuation of treatment. There was no significant change observed in blood pressure, hematologic, hepatic, and renal functions during treatment with NeuroAid and up to 3 months after completion of a 3-month regimen. These data confirm the excellent safety profile of NeuroAiD in patients with acute ischemic stroke during treatment and long after completion of treatment.
Shahripour RB, et al. Chin J Integr Med 2014. DOI: 10.1007/s11655-014-1687-8
Click here to open the publication
This study on 114 patients with acute ischemic stroke randomized within 48 hours of onset shows that serious adverse events (SAEs) were similar between the group treated with placebo and the group treated with MLC601. The SAEs reported were those commonly seen in stroke patients. There were neither statistically or clinically significant differences between treatment groups in biochemical, haematological, or electrocardiogram tests at 3 months, nor any statistically or clinically significant differences in the absolute and relative changes of the various parameters between baseline and 3 months. Thus, MLC601 is safe for patients with acute stroke receiving a 3-month treatment.
Young SHY, et al. Cerebrovasc Dis 2010. DOI: 10.1159/000313398
Click here to open the publication

Additional Data

NeuroAiD does not significantly affect hematological, hemostatic, and biochemical parameters in normal and stroke patients. Clinical parameters and expected effects of aspirin are not altered by co-administration of the drug even when started and maintained at the early stage of acute stroke.
Gan R, et al. Cerebrovasc Dis 2008. DOI: 10.1159/000126919
Click here to open the publication

II. Traumatic Brain Injury – Neurosurgical pathologies

Clinical data – Efficacy

This randomized controlled trial included 32 subjects with non-surgical moderate traumatic brain injury (TBI) allocated to receive standard TBI treatment with or without MLC601 over three months. The MLC601 group had a numerically higher Glasgow Outcome Scale (GOS) score than the control group at all observation timepoints. The Barthel Index (BI) values indicated a significant improvement for the MLC601 group at M3, with a favourable trend at M6. No adverse effects were noted. MLC601 showed potential for a positive effect on TBI outcome with no adverse effects.
Fauzi AA, Prihastomo KT, Ranuh IGMAR et al. Brain Sci 2020;10;60:1-9. DOI: 10.3390/brainsci10020060
Click here to open the publication
This was a 9-month pilot, randomized placebo-controlled clinical trial to examine the safety and potential effects of the herbal supplement MLC901 (NeuroAiD II) on cognitive functioning following TBI. As rersistent cognitive deficits have been reported to affect 15 –40% of adults post-TBI, investigators wanted to evaluate the effects of MLC901 in these patients. This study demonstrated that MLC901 was safe and well tolerated post‐TBI. This study provided Class I/II evidence that, for patients with mild to moderate TBI, 6 months of MLC901 improved cognitive functioning.
A. Theadom et al. Eur J Neurol. 2018 Apr 3. DOI: 10.1111/ene.13653
Click here to open the publication
The study aims to evaluate the efficacy of MLC901 on the neurological outcome of patient after moderate (GCS 9-12) to severe (GCS 3-8) traumatic brain Injury. Patients were randomized to receive MLC901 or placebo for six months with an intention to treat analysis. Assessment was carried out using mRS and GOS at baseline, 3 months and at 6 months follow up. Result showed functional outcome of mRS and GOS at 3 and 6 months were significantly better compared to placebo. The study highlights the promising efficacy of MLC901 in patients suffering from moderate to severe TBI.
Hussein Pakdaman, et al Open access journal of Complementary and Alternative Medicine DOI: 10.32474/ OAJCAM.2020.02.000148
Click here to open the publication
This case series report of 20 patients treated with MLC601 in the Neurosurgery division of National University Hospital in Singapore. All patients received 4 capsules of MLC601 3 times a day for 3 months started within 3 months of onset of brain injury or stroke. All patients reported some improvements and good tolerance for the drug. Three cases (head injury, hemorrhagic stroke from AVM, and brain abscess) with remarkable outcomes were presented, illustrating how it may not be unreasonable to prescribe MLC601 to selected patients with difficult neurosurgical pathology in the hope that the neurological function outcome would improve.
Yeo TT, et al. Poster WSC Seoul 2010. http://moleac.com/pubs/case_report_on_the_use_of_mlc601_(neuroaid)_in_neurosurgical_pathologies_-_yeo_tt_-_2010.pdf
Click here to open the publication

III. Cognitive Disorders and Dementia

Following Alzheimer’s disease (AD), Vascular Dementia (VaD) is the second most common cause of dementia in elderly people with lack of available effective treatment. Several studies and clinical trials have demonstrated the benefits of MLC601 (NeuroAiD) in post-stroke recovery and AD. This pilot trial was multicenter, randomized, double-blind, aiming to investigate the efficacy and safety of NeuroAiD in patients suffering from VaD. This is the first study conducted on NeuroAiD to investigate its efficacy in VaD as well as duration of treatment over 24 months. Repeated measures analyses showed that both MMSE and ADAS-cog scores were significantly better in the treatment group at 24 months. This long-term treatment with NeuroAiD was well-tolerated without reported serious adverse events.
Pakdaman H, et al. Neuropsychiatric Disease and Treatment 2017. DOI: 10.2147/NDT.S145047
Click here to open the publication
This publication is a multicenter, nonblinded, randomized controlled trial, which included 264 volunteers with AD to evaluate the effectiveness and safety of MLC601 in the treatment of mild to moderate AD as compared to 3 approved cholinesterase inhibitors (ChEIs) including donepezil, rivastigmine and galantamine. This is the second clinical study of NeuroAiD™ effectiveness and safety in Alzheimer disease. In a previous clinical trial study, NeuroAiD™ has demonstrated a favorable tolerability and encouraging effectiveness on cognitive function in Alzheimer disease patients during 18 months of treatment when compared to rivastigmine. In this study, the authors have shown that NeuroAiD™ has favorable effects on cognitive functions during 16 months of follow-up, with improvements on cognitive function specifically observed in the first 8 months of treatment. NeuroAiD™ is as effective as other commonly used Cholinesterase inhibitors (Donepazil, Rivastigmine, Galantamine) in treating cognitive deficits. Finally, NeuroAiD™ has shown a better tolerability profile compared to the 3 ChEIs, which implies a better compliance for patients.
Pakdaman, H et al. Dementia and Geriatric Cognitive Disorders 2015. DOI: 10.1159/000375295
Click here to open the publication
The aim of this early stage “proof-of-concept” clinical study was to evaluate the efficacy and tolerability of MLC601 in patients with mild to moderate Alzheimer disease (AD). The results showed that NeuroAiD was well-tolerated even up to 18 months of treatment. This tolerability represents a key improvement compared to current AD treatments, i.e. ChEIs, in which a modest but significant therapeutic effect is often compromised by the occurrence of adverse events and discontinuation of treatment.
Harandi AA, et al. Brit Med Med Res 2013. http://moleac.com/pubs/efficacy_and_tolerability_of_mlc601_in_patients_with_mild_to_moderate_alzheimer_disease_-_pakdaman_et_al_-_2013.pdf
Click here to open the publication
This was an open-label extension study evaluating the efficacy and safety of MLC601 in patients with mild to moderate AD. The rationale behind this study is supported by current evidence on the long-term efficacy of MLC601 in post-stroke recovery, by positive results in the treatment of dementia and minimal cognitive impairment. The efficacy of treating AD patients with MLC601 over 4 years has been demonstrated in the study. Overall, it seems that the safety and efficacy of MLC601 is promising compared to currently prescribed treatments.
Pakdaman et al. Dement Geriatr Cogn Disord Extra 2018. DOI: 10.1159/000488482
Click here to open the publication
The researchers decided to conduct this study knowing the promising effect of MLC601 (NeuroAiD) in Alzheimer’s disease. They designed a pilot, randomized, double-blind, placebo-controlled study aiming at evaluating the efficacy and the safety of MLC601 in patients with Mild Cognitive Impairments (MCI). MCI is characterized by a decline of the cognitive function greater than that expected for a person’s age, with a possible progress into dementia. Seventy-two patients were receiving NeuroAiD or placebo during 6 months (M) with an evaluation of global cognitive function performed with two different scales (MMSE and ADAScog) at baseline, M3, and M6 follow-up visits. A repeated-measures analysis carried out based on both scales’ score, showed a statistically significant difference between the placebo and the MLC601 group during the 6 months of follow-up. Overall, the tolerability of the product was good with only 5 patients reporting transient and tolerable gastrointestinal disorders.
Pakdaman H, et al. Dementia and Geriatric Cognitive Disorders 2017. DOI: 10.1159/000458521
Click here to open the publication

IV. Preclinical Data – Pharmacology

Cognitive Disorders and Dementia

The purpose of this paper was to investigate the effects of MLC601 (NeuroAiD) on regulation of APP (Amyloid Precursor Protein) processing. Human neuroblastoma cell line SH-SY5Y was used for all experiments. Cells were treated with different concentration of NeuroAiD before assessing changes in the levels of released lactate dehydrogenase (LDH), full-length APP and secreted sAPPα. In conclusion it appears that NeuroAiD is a possible modulator of APP processing and has implications as a putative therapeutic strategy for the treatment of post stroke dementia and AD.
Lim YA, et al. Cerebrovasc Dis 2013. DOI: 10.1159/000346236
Click here to open the publication
The presence of neurofibrillary tangles (NFTs) in the brain is characteristic of neurodegenerative diseases including Alzheimer’s disease and frontotemporal dementia due to the hyperphosphorylation of the tau protein. The objective of this study was to assess the effects of MLC901 (NeuroAiDTMII) on ameliorating tau phosphorylation at epitopes associated with formation of NFTs. Results support evidence for a role of MLC901 in mediating this effect by inhibiting kinases (GSK3β and cdk5) leading to a significant decrease of tau phosphorylation. Previous studies (pre-clinical and clinical) having demonstrated the effect of MLC601 (NeuroAiD) as a promising therapeutic strategy for Alzheimer’s disease, this paper provides a new understanding of its multimodal mechanisms of action in this promising indication.
Lee WT, et al. NeuroReport 2017. DOI: 10.1097/WNR.0000000000000884
Click here to open the publication

Stroke

Key Data

This paper reviews the pharmacological effects of NeuroAiD on the normal and ischemic brain and neurons. In vivo and in vitro experiments using mouse model of stroke (focal ischemia), rat model of cardiac arrest (global ischemia) and cortical neurons in culture were reviewed and summarized. In conclusion NeuroAID demonstrated both neuroprotective and neuroregenerative properties in rodent models of focal and global ischemia and in cortical cell cultures.
Heurteaux C, et al. Cerebrovasc Dis 2013. DOI: 10.1159/000346228
Click here to open the publication
The paper describes the results of a series of in vivo and in vitro experiments demonstrating the neuroprotective and neuroproliferative effects of NeuroAiD when given prior to and/or after injury in rodent models of ischemic stroke and neuronal injuries, human embryonic stem cells, and neuronal cell cultures. It shows how NeuroAiD supports neuroplasticity by its effect on neurogenesis, neuritic outgrowth, and synaptogenesis. NeuroAiD provides a better milieu for post-stroke recovery and decreases neurological impairments.
Heurteaux C, et al. Neuropharmacology 2010. DOI: 10.1016/j.neuropharm.2010.01.001
Click here to open the publication
The paper describes the results of a series of in vivo experiments demonstrating neuroprotective and neurogenesis effects of MLC901 on hippocampal CA1 region against global ischemia in rodent models of global ischemia. It shows how neuronal protection by MLC901 is likely mediated by the Akt protein (a central mediator in the signal transduction pathway involved in cell survival) and reduction of oxidative stress. MLC901 prevents necrosis and apoptotic cell death induced by global ischemia, enhances neurogenesis, and enhances functional recovery. This makes MLC901 a potential novel therapeutic strategy in treating cognitive and neurological deficits caused by global ischemia from conditions that deprive the brain of oxygen and glucose, such as cardiac arrest.
Quintard H, et al. Neuropharmacology 2011. DOI: 10.1016/j.neuropharm.2011.05.003
Click here to open the publication
This study was designed to learn more about NeuroAiD™II’s cellular and molecular mechanisms of action on human neurons and more precisely by investigating the impact of MLC901 on human neural progenitor cells undergoing neural differentiation. Genes having a role in neurogenesis and neural differentiation were found significantly regulated by MLC901 in three independent experiments. The researchers identified genes of functional pathways regulated by MLC901 that could promote neurogenesis and neuroprotection in the human brain, and offered some insights into the possible mechanism of action of MLC901. After extensive studies in cell and animal models previously published, this paper provides the first validation, in human cells of the neuroplasticity mechanism triggered by MLC901, and whose effects are observed in clinical trials on recovery.
HYA Chan, et al. The Pharmacogenomics Journal 2016. DOI: 10.1038/tpj.2016.21
Click here to open the publication
This in-vivo study conducted by the CNRS (National Center for Scientific Research, France) is providing further evidence of MLC901 (NeuroAiDTMII) multimodal mechanism of action and particularly interesting to better understand a possible cardioprotective effect. A previous study, published in Stroke in 2013, demonstrated the benefits of NeuroAiD in reducing the risk of early vascular events in post-stroke victims, up to 3 months following stroke onset (Chen C, et al. Stroke 2013.). The researchers aimed at evaluating the acute and long-term benefits of MLC901 (NeuroAiDTMII) in ischemic and reperfused mouse heart models. This paper demonstrates that MLC901 treatment was able to provide acute and long-term cardioprotective effects in a murine model of myocardial ischemia-reperfusion injury in vivo.
Vincent a, et al. Scientific reports 2017. DOI: 10.1038/s41598-017-14822-x
Click here to open the publication

Additional Data

This study investigates the potential anti-inflammatory effects of MLC901 (NeuroAiD™II) in a model of transient focal cerebral ischemia in mice (60-min middle cerebral artery occlusion), and analyzes the effect of MLC901 on the different mechanisms that trigger the inflammatory process. MLC901 increases survival after MCAO, reduces the infarct volume, and improves the neurological score. These are in line with previous preclinical results and clinical trials. The major effects of MLC901 are: 1) the reduction of neutrophil recruitment, 2) the reduction of microglia activation, and 3) the reduction of pro-inflammatory mediators (TNFα, IL6, IL1β, CCL2) production induced by stroke. The present work confirms that MLC901 significantly protects mice against brain injury after focal ischemia and represents a promising therapeutic strategy for brain injuries, and particularly stroke treatment.
Widmann C, et al. Scientific reports 2018. DOI: 10.1038/s41598-018-36138-0
Click here to open the publication
This in-vivo study conducted by the CNRS (National Center for Scientific Research, France) is providing further evidence of MLC901 (NeuroAiDTMII) multimodal mechanism of action and particularly interesting to better understand a possible cardioprotective effect. A previous study, published in Stroke in 2013, demonstrated the benefits of NeuroAiD in reducing the risk of early vascular events in post-stroke victims, up to 3 months following stroke onset (Chen C, et al. Stroke 2013.). The researchers aimed at evaluating the acute and long-term benefits of MLC901 (NeuroAiDTMII) in ischemic and reperfused mouse heart models. This paper demonstrates that MLC901 treatment was able to provide acute and long-term cardioprotective effects in a murine model of myocardial ischemia-reperfusion injury in vivo.
Vincent a, et al. Scientific reports 2017. DOI: 10.1038/s41598-017-14822-x
Click here to open the publication
NeuroAiD™II (MLC901) has already demonstrated neuroprotective and neuroreparative properties and is also proven to improve long-term post-stroke recovery in human. In humans, vascular remodeling takes place 3 or 4 days after stroke, facilitating the processes of neurorepair. Therapeutic angiogenesis is an approach of regenerative medicine that may help in improving the outcomes of patients after an ischemic stroke. Because the neural and vascular cell crosstalk is important in brain repair, Dr. Catherine Heurteaux and her team at CNRS (National Center for Scientific Research, France) decided to further investigate the effect of MLC901 on vascular remodeling in a model of focal ischemia in mice. This study has provided evidences that MLC901 enhances endothelial cell proliferation and vascular remodeling locally in the ipsilateral infarcted area, but not in the contralateral hemisphere, showing that MLC901 is stimulating only the natural local revascularization process. This key finding highlights the role of MLC901 in stimulating revascularization, neuroprotection and repair of the neurovascular niche after ischemic stroke.
Gandin C, et al. Cerebrovasc Diseases 2016. DOI: 10.1159/000444810
Click here to open the publication
This paper highlights the potency of NeuroAid in neuroprotection with the discovery of a key underlying mechanism of action. The activation by NeuroAid of the ATP-sensitive potassium channel located in the suffering neurons of the brain protects them from death. Indeed, the opening of the channel decreases the excitability of neurons (by hyperpolarization) preventing an overload of calcium and release of excitotoxic glutamate. Besides the beneficial effects in neuroplasticity already published, these results strengthen the interest of NeuroAid in stroke recovery.
Moha Ou Maati H, et al. Neuropharmacology 2012. DOI: 10.1016/j.neuropharm.2012.05.035
Click here to open the publication

Traumatic Brain Injury

This paper demonstrates how NeuroAiD™ can be beneficial in reducing the deleterious consequences induced by Traumatic Brain Injury (TBI) and highlights NeuroAiD™ properties in a rat model of TBI. This is the first publication on the pharmacological actions of NeuroAiD™ in TBI and in which its multimodal mechanisms as well as its time-effect have been demonstrated. Adding to NeuroAiD™ beneficial effects in ischemic stroke recovery, this work provides evidence that NeuroAiD™ has neuroprotective and neurorestorative actions which lead to an improvement in the recovery of cognitive functions in an animal model of TBI, hence providing a rationale for NeuroAiD™ to improve recovery of patients with TBI.
Quintard H, et al. Neuroscience 2014. DOI: 10.1016/j.neuroscience.2014.06.047
Click here to open the publication
Many post-Traumatic Brain Injury’s (TBI) processes are mediated by the Transforming growth factor-beta 1 (TGF-β1) expressed by microglial cells. Previous studies identified the activity of NeuroAiD in reducing microglia activation in rats with TBI. This in-vivo studies, conducted on rats, aimed at investigating whether NeuroAiD or Astragaloside (also known to attenuate microglia activation) improves output of TBI by affecting microglial expression of TGF-β1. The researchers found that both NeuroAiD and Astragaloside significantly reduced TBI-induced brain contused volume, neurological severity score and the number of TGF-β1 containing microglia. This is another demonstration of NeuroAiD’s neuroprotective effect, already highlighted in several published pre-clinical studies.
Chio CC, et al. 2016. DOI: 10.1111/eci.12693
Click here to open the publication
This paper highlights the role of MLC601 in improving recovery as well as affecting microglial activation in a model of rats with induced TBI. Early treatment with MLC601 (1h post-TBI) has shown significantly better benefits in reducing TBI-induced cerebral contusion than a late treatment. Beneficial effects of MLC601 were correlated with reduction in neurological and motor deficits, neuronal apoptosis and microglial activation (microgliosis, morphological transformation of microglia and microglial overexpression of TNF-α). These results are consistent in part with the beneficial effects of MLC901 in a model of rats with induced TBI already published. This work provides further evidence and a rationale to use MLC601 or MLC901 therapy in improving functional recovery in patients with TBI.
Tsai MC, et al. J Neuroimmune Pharmacol 2014. DOI: 10.1007/s11481-014-9570-0
Click here to open the publication

V. Ongoing clinical Trials

With limited therapeutic options in the current treatment of spinal cord injury (SCI), many patients with SCI remain disabled. Spinal Cord Injury—Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (SATURN) investigates the promising role of NeuroAiD in SCI especially given its excellent safety profile. SATURN is a prospective cohort study of patients with moderately severe to severe SCI, defined as American Spinal Injury Association (ASIA) Impairment Scale (AIS) A and B. The results will provide important information on the feasibility of conducting larger controlled trials to improve long-term outcome of patients with SCI.
Kumar JC et al. JMIR Res Protoc 2016. DOI: 10.2196/resprot.6275
Click here to open the publication
This imaging substudy aims to assess the efficacy of NeuroAiD in subgroups of patients randomized in the main CHIMES Study when categorized according to baseline imaging characteristics. Acute stroke lesions on baseline CT or MRI are reviewed in terms of size, location, and extent of involvement by two readers who remain blinded to treatment allocation and outcomes of the subjects. The outcomes, namely modified Rankin Scale, National Institute of Health Stroke Scale, Barthel Index, and Mini-Mental Status Examination, will be analyzed by the sub-groups nonlacunar and lacunar, cortical and sub-cortical, hemispheric vs. brainstem, Alberta Stroke Program Early CT score.
Navarro JC et al. Int J Stroke 2013. DOI: 10.1111/ijs.12044
Click here to open the publication

VI. NeST Registry

The NeuroAiD Safe Treatment (NeST) Registry works as a product registry to provide information on the use of NeuroAiD and monitor its safety in a real world setting. The NeST Registry is a proactive industry-academic effort designed to be as unobtrusive as possible during its assessment hence an online framework was introduced for easier data entry and retrieval of clinical information. The registry also acts as a complement for more accurate pharmacovigilance, essential for patient care and surveillance. Participation is voluntary and patients’ data is anonymous.
Venketasubramanian N, et al. BJM Open 2015. DOI: 10.1136/bmjopen-2015-009866
Click here to open the publication

NeuroAiD is available in over 32 countries.

 

Moleac has developed multiple partnerships with companies sharing the same values and vision to deliver innovative solutions in each market and address medical unmet needs, particularly in post-stroke and post-traumatic brain injury recovery.

Our growing network of partners ensures the availability of NeuroAiD to an even greater number of stroke victims and victims of traumatic brain injuries worldwide but also patients experiencing cognitive decline.

Since 2006, NeuroAiD has expended its presence to over 32 countries and we still aim to make NeuroAiD available to more patients in need worldwide.

Moleac Offices

Our Partners

Disclaimers:  This webpage provides scientific data and information exclusively meant for healthcare professionals. NeuroAiD™ II is a trademark of Moleac. MLC601 and MLC901 are 2 different proprietary formulations which have been shown to be equivalent in pharmacology and are referred as NeuroAiD on this webpage.

Find-out if NeuroAiD is right for you.

Leave your questions to our Customer Care team by clicking on the box below. Always seek advice from your physician.

ASK YOUR QUESTIONS